Overview

Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.

Status:
Enrolling by invitation
Trial end date:
2023-04-15
Target enrollment:
Participant gender:
Summary
This is an open-label study to evaluate the long-term efficacy and safety of KZR-616 in patients with active PM or DM who completed the double-blind treatment period of Study KZR-616-003, up to and including the Week 32 Visit, prior to the first dose of open-label KZR-616.
Phase:
Phase 2
Details
Lead Sponsor:
Kezar Life Sciences, Inc.